Luke Halpern, Associate Editor

Allison Burns, president and CEO of EMO Health, discusses the price point and stigma surrounding OTC naloxone in an interview with Pharmacy Times.

An analysis of interaction checkers and product summaries revealed large differences in the consistency and reliability of providing accurate information on potential drug-drug interactions.

In pediatric and adult patients, the top 3 surgical procedures accounted for the highest share of opioid prescriptions, indicating a need for better opioid prescription management and greater awareness of the possible opioid-related adverse events that can stem from prescriptions of the drug.

In a follow-up to the interim FTC report documenting the business practices of PBMs and the power they hold in the pharmaceutical industry, the Commission now seeks to sue the 3 largest PBMs in the country for driving up the price of insulin and other essential drugs.

Intravenous immunoglobulin was effective as an adjunctive treatment to anticoagulation in a patient with post-viral platelet-activating anti-PF4 disorder, indicating the need for accurate diagnosis and treatment selection.

The RECTIFIER framework was able to screen patients with heart failure more accurately and with a cheaper cost than traditional screening methods.

In a new report, the FTC says pharmacy benefit managers act as middlemen in the pharmaceutical industry, leading to the squeezing of independent pharmacies and increases in prices for patients.

Individuals with tattoos were found to have a greater risk of developing malignant lymphoma, with the risk being highest within 2 years of receiving a tattoo.

Following the previous FDA approval of faricimab-svoa to treat some of the leading causes of vision loss, the Administration has approved a single-dose prefilled syringe of the drug which could lead to safer and more efficient administration while easing patient burden.

By developing the Shizuoka score, which features a new predictive model using machine learning, patients with Kawasaki disease who are non-responders to intravenous immunoglobulin were able to be accurately identified.

Researchers found that certain mutations in KLHL6 can lead to an increase in the number of B-cell receptors, resulting in poor outcomes for patients with diffuse large B-cell lymphoma.

This narrative review dispels the long-held belief that reduction in salt intake leads to better health outcomes in patients with heart failure.

As dupilumab garners positive clinical trial results in patients with chronic obstructive pulmonary disease, it is increasingly important that pharmacists educate themselves on the treatment.

The committee, after being presented evidence by the working group, recommended the vaccine for adults aged 65 and older and those 19 or older who have current recommendations to receive a pneumococcal vaccine.

In a rare case of non-tumor anti-Tr/DNER antibody-associated ataxia, the patient is treated with plasmapheresis and intravenous immunoglobulin (IVIG) for symptoms such as dysarthria and difficulty walking.

This is the first novel, precision mechanism of action to be released to treat patients with CIDP in over 3 decades.

Increased immunoglobulin replacement therapy led to reduced infections and managed secondary immune deficiencies such as hypogammaglobulinemia.

RCT1100 is designed to deliver DNAI1 mRNA directly to affected airways through an inhaled nebulizer and fills an urgent unmet need in the treatment of those with primary ciliary dyskinesia.

Combining multiple drugs to induce a deep response in patients with diffuse large B-cell lymphoma could open curative pathways for those affected.

Health professionals have expressed concerns regarding consistent naming standards, the regulatory process surrounding the approval of biosimilar drugs, and the lack of education they have about biosimilars.

After over 2 decades, the first inhaled product with a novel mechanism of action has been approved by the FDA for the treatment of chronic obtrusive pulmonary disorder.

Compared to placebo, nicotinamide riboside significantly improved the 6-minute walking capabilities in patients with decreased endurance and muscle function due to peripheral artery disease.

After being previously approved in June 2023 under an Accelerated Approval process, the FDA has granted an expanded approval for non-ambulatory individuals and individuals 4 years of age or older.

Participants in the study had durable response for over 1 year, in addition to positive efficacy indicators.

A panel hosted by HOPA, ACCC, and AVAHO discusses strategies to ensure patient access to treatment.

Perhaps the most significant development in the pharmaceutical industry in decades, crops of biosimilars are being approved and are ready for distribution. What lies next, in terms of legislation and the impact on pharmacists, remains to be seen.

The research was aided by the Decipher Genomics Resource for Intelligent Discovery, which helped derive the gene signatures used during the analysis.

The drug can now be tested for safety, tolerability, and efficacy in a phase 1 study.

The drug is the first approved antiviral COVID-19 treatment that could be used across all stages of liver disease.

Protection of T cells from tumor-induced suppression suggests potential for enhancing efficacy of therapies, with plans to initiate a phase 1/2 clinical trial in patients with advanced breast cancer.